Transcriptomics

Dataset Information

0

Gene expression profile of multiple myeloma cell lines treated with CB-5083


ABSTRACT: The goal was to determine the gene expression differences between CB-5083 and Bortezomib treated multiple myeloma cell lines Inhibition of the AAA ATPase, p97, was recently shown to be a novel method for targeting the ubiquitin proteasome system (UPS) and CB-5083, a first in class inhibitor of p97, has demonstrated broad antitumor activity in a range of both hematological and solid tumor models. Here, we show that CB-5083 has robust activity against multiple myeloma (MM) cell lines and a number of in vivo MM models. Treatment with CB-5083 is associated with accumulation of ubiquitinated proteins, induction of the unfolded protein response (UPR) and apoptosis. CB-5083 decreases viability in MM cell lines and patient derived MM cells, including those with background proteasome inhibitor (PI) resistance. CB-5083 has a unique mechanism of action that combines well with PIs which is likely owing to the p97-dependent retro-translocation of the transcription factor, Nrf1, which transcribes proteasome subunit genes following exposure to a PI. In vivo studies using clinically relevant MM models demonstrate that single-agent CB-5083 inhibits tumor growth and combines well with MM standard of care agents. Our preclinical data demonstrate the efficacy of CB-5083 in several MM disease models and provide the rationale for clinical evaluation as monotherapy and in combination in MM.

ORGANISM(S): Homo sapiens

PROVIDER: GSE101923 | GEO | 2017/10/26

SECONDARY ACCESSION(S): PRJNA395929

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2024-08-19 | GSE271840 | GEO
2024-08-19 | GSE271838 | GEO
2015-11-09 | E-GEOD-73588 | biostudies-arrayexpress
2022-05-19 | PXD025898 | Pride
2015-11-09 | GSE73588 | GEO
| PRJNA297366 | ENA
2022-08-01 | PXD032316 | Pride
2024-09-15 | GSE184310 | GEO
2020-04-15 | GSE148659 | GEO
2020-02-18 | GSE124510 | GEO